{"source_content":"2020年08月血制品行业批签发跟踪证券研究报告2020年09月医药生物投资评级推荐维持分析师:常启辉执业资格证：S0020517090001电话:021-51097188E-MAIL:changqihui@gyzq.com.cn联系人：刘巧电话：021-51097188E-MAIL：liuqiao@gyzq.com.cn联系人：汤芬芬电话：021-51097188E-MAIL：tangfenfen@gyzq.com.cn联系人:刘慧敏电话:021-51097188E-MAIL:liuhuimin@gyzq.com.cn请务必阅读正文之后的免责条款部分【国元医药】血液制品-月度行业报告2投资摘要：•8月血制品总计实现批签发756.53万瓶，同比下降6.59%，环比增长12.79%。2020年1-8月累计批签发6437万瓶，同比增长27.77%，疫情控制后，整体批签发情况趋稳。•白蛋白本月累计批签发481.27万瓶，同比增长12.04%，其中进口占52.59%，进口白蛋白批签量本月有所恢复，国产与进口占比几乎持平，本月国产白蛋白批签量创今年来新高(达228.16万瓶)，主要来自泰邦、莱士、天坛、华兰等国产巨头的贡献；静丙本月批签发98.32万瓶，同比下降18.52%，与上月基本持平，疫情后静丙批签发逐渐稳定。•海外血制品公司疫情下采浆下滑，或将影响国内进口白蛋白供给。新冠疫情下，国内2020H1采浆量较去年同期下降近1000吨，但随着疫情得到控制，Q2国内采浆节奏逐步恢复。海外疫情尚未完全恢复，采浆的影响或将持续，根据CSL披露信息，公司20财年整体采浆量同比下滑5%，7月采浆量有所恢复但8月份美国热点地区疫情再度爆发，预计20年Q4下滑20-30%。CSL作为我国白蛋白批签发量最高的企业，其采浆量的下滑可能影响后续进口白蛋白的供给，国内白蛋白或将进入低供给、提升价格的新周期。•采浆成本提升，有望推动血制品价格进入上升通道。疫情下血制品公司需要配备新冠检测试剂，增添防护用的口罩、手套等，浆站的采浆成本、检测成本上升，CSL也在业绩说明会中表示由于疫情的影响，其20财年的采浆成本增加了约9%，成本上升或将进一步推动血制品价格上行。•投资评级：血制品行业景气度较高，我们维持推荐评级，建议关注天坛生物、华兰生物等血液制品行业龙头企业。•风险提示：血浆供应不及预期、行业监管风险、生产安全性风险、政策风险。资料来源：中检院及各地方所，国元证券研究中心注：本文采用数据均进行标化。请务必阅读正文之后的免责条款部分【国元医药】血液制品批签发数据跟踪by2020083本月批签发重点品种及主要观点：8月血制品总计实现批签发756.53万瓶，同比下降6.59%，环比增长12.79%，整体批签发情况趋稳。白蛋白批签发481.27万瓶，同比增长12.04%，其中进口白蛋白批签发253.11万，占52.59%，进口白蛋白批签量本月有所恢复；国产白蛋白批签发228.16万，国产占比与进口基本持平，本月国产白蛋白批签量达今年来新高，主要来自泰邦、莱士、天坛、华兰等国产巨头的贡献。本月静丙批签发98.32万瓶，同比下降18.52%，较上月基本持平，疫情后静丙批签发趋于稳定。其他品种：本月狂免批签发92.66万、破免31.70万、乙免5.03万、肌丙12.39万、纤原5.94万、八因子21.75万、PCC7.46万。本月重点企业批签发情况：天坛生物本月批签发54.77万瓶，包括白蛋白32.47万、静丙22.29万，公司本月批签量下滑主要系本月仅有两大产品有批签发。华兰生物本月批签发90.63瓶，包括白蛋白32.45万、静丙5.51万、狂免20.84万、破18.09万、乙免3.38万、八因子5.32万、PCC5.04万，公司本月批签发恢复较好，多个产品批签量增幅显著。博雅生物本月批签发7.01万瓶，包括白蛋白3.09万、静丙3.92万，公司静丙批签量本月恢复，白蛋白有所下滑。上海莱士本月批签发87.46万瓶，包括白蛋白39.98万、静丙12.52万、狂免19.71万、八因子7.31万、纤原5.94万，公司白蛋白批签量达今年来的新高，纤原批签发恢复并贡献本月国内所有纤原批签发。泰邦生物本月批签发90.07万瓶，包括白蛋白45.45万、静丙17.59万、肌丙4.64万、狂免11.68万、破免7.54万、八因子1.74万、PCC1.43万。双林生物本月批签发39.07万瓶，包括白蛋白10.60万、狂免22.40万、破免6.08万。资料来源：中检院及各地方所，国元证券研究中心请务必阅读正文之后的免责条款部分重点品种跟踪4资料来源：中检院及各地方所，国元证券研究中心请务必阅读正文之后的免责条款部分重点品种跟踪5白蛋白资料来源：中检院及各地方所，国元证券研究中心静丙肌丙本月白蛋白批签发481.27万瓶，同比增长12.04%进口白蛋白批签发253.11万，占52.59%，主要来自CSL(20.65%)、Grifols(12.79%)、Baxalta(11.08%)国产白蛋白批签发228.16万，占比与进口基本持平，主要来自泰邦(9.44%)、莱士(8.31%)、天坛(6.75%)、华兰(6.74%)本月静丙批签发98.32万瓶，同比下降18.52%，主要来自天坛(22.67%、泰邦(17.89%)、上海莱士(14.77%)、派斯菲科(13.04%)、山西康宝(8.12%)、华兰生物(5.61%)静丙批签量在疫情后趋于稳定本月肌丙批签发12.39万瓶，来自博晖创新(43.43%)、泰邦生物(37.47%)、新疆德源(19.09%)请务必阅读正文之后的免责条款部分重点品种跟踪6资料来源：中检院及各地方所，国元证券研究中心狂免破免乙免本月狂免批签发92.66万瓶，略低于上月，批签发来自双林生物(24.18%)、华兰生物(22.49%)、上海莱士(21.27%)、远大蜀阳(19.46%)、泰邦生物(12.60%)本月破免批签发31.70万瓶，与上月持平，来自华兰生物(57.06%)、泰邦生物(23.77%)、双林生物(19.17%)本月乙免批签发5.03万瓶，批签发来自华兰生物(67.23%)、远大蜀阳(32.77%)请务必阅读正文之后的免责条款部分重点品种跟踪7资料来源：中检院及各地方所，国元证券研究中心纤维蛋白原凝血酶原复合物凝血因子VIII本月纤原批签发5.94万瓶，同比下降9.22%，全部来自泰邦上海莱士(100%)本月八因子批签发21.75万瓶，同比增长15.96%，来自绿十字(33.94%)、上海莱士(33.59%)、华兰生物(24.46%)、泰邦生物(8.01%)本月PCC批签发7.46万瓶，与上月基本持平，来自华兰生物(67.57%)、泰邦生物(19.14%)、南岳生物(13.30%)南岳生物PCC本月首次获得批签发请务必阅读正文之后的免责条款部分重点公司跟踪8天坛生物本月批签发54.77万瓶，同比降低37.92%，包括白蛋白32.47万、静丙22.29万，其余品种未有批签发。截止8月公司已完成去年整体批签发的64.88%。批签量下滑主要系本月仅有两大产品有批签发，预计公司处于调整中。本月批签发7.01万瓶，包括白蛋白3.09万、静丙3.92万，其余品种未有批签发。截止8月公司已完成去年整体批签发的77.83%。公司静丙批签量本月恢复，白蛋白有所下滑。本月批签发90.63瓶，包括白蛋白32.45万、静丙5.51万、狂免20.84万、破18.09万、乙免3.38万、八因子5.32万、PCC5.04万，其余品种未有批签发，批签发恢复至去年同期水平。截止8月公司已完成去年整体批签发的67.73%。资料来源：中检院及各地方所，国元证券研究中心华兰生物博雅生物请务必阅读正文之后的免责条款部分重点公司跟踪9上海莱士本月批签发87.46万瓶，同比增长12.20%，包括白蛋白39.98万、静丙12.52万、狂免19.71万、八因子7.31万、纤原5.94万。截止8月公司已完成去年整体批签发的78.20%。白蛋白批签量达今年来的新高，纤原批签发恢复并成为本月唯一获得纤原批签发的企业。本月批签发39.07万瓶，包括白蛋白10.60万、狂免22.40万、破免6.08万，其余品种未有批签发。截止8月公司已完成去年整体批签发的68.24%。本月批签发90.07万瓶，包括白蛋白45.45万、静丙17.59万、肌丙4.64万、狂免11.68万、破免7.54万、八因子1.74万、PCC1.43万，其余品种未有批签发。截止8月公司已完成去年整体批签发的80.95%。资料来源：中检院及各地方所，国元证券研究中心泰邦生物双林生物请务必阅读正文之后的免责条款部分10分析师声明作者具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，以勤勉的职业态度，独立、客观地出具本报告。本人承诺报告所采用的数据均来自合规渠道，分析逻辑基于作者的职业操守和专业能力，本报告清晰准确地反映了本人的研究观点并通过合理判断得出结论，结论不受任何第三方的授意、影响。证券投资咨询业务的说明根据中国证监会颁发的《经营证券业务许可证》(Z23834000),国元证券股份有限公司具备中国证监会核准的证券投资咨询业务资格。证券投资咨询业务是指取得监管部门颁发的相关资格的机构及其咨询人员为证券投资者或客户提供证券投资的相关信息、分析、预测或建议，并直接或间接收取服务费用的活动。证券研究报告是证券投资咨询业务的一种基本形式，指证券公司、证券投资咨询机构对证券及证券相关产品的价值、市场走势或者相关影响因素进行分析，形成证券估值、投资评级等投资分析意见，制作证券研究报告，并向客户发布的行为。（1）公司评级定义（2）行业评级定义买入预计未来6个月内，股价涨跌幅优于上证指数20%以上推荐预计未来6个月内，行业指数表现优于市场指数10%以上中性预计未来6个月内，行业指数表现介于市场指数±10%之间回避预计未来6个月内，行业指数表现劣于市场指数10%以上增持预计未来6个月内，股价涨跌幅优于上证指数5-20%之间持有预计未来6个月内，股价涨跌幅介于上证指数±5%之间卖出预计未来6个月内，股价涨跌幅劣于上证指数5%以上请务必阅读正文之后的免责条款部分11一般性声明本报告仅供国元证券股份有限公司(以下简称“本公司”)的客户使用。本公司不会因接收人收到本报告而视其为客户。若国元证券以外的金融机构或任何第三方机构发送本报告，则由该金融机构或第三方机构独自为此发送行为负责。本报告不构成国元证券向发送本报告的金融机构或第三方机构之客户提供的投资建议，国元证券及其员工亦不为上述金融机构或第三方机构之客户因使用本报告或报告载述的内容引起的直接或连带损失承担任何责任。本报告是基于本公司认为可靠的已公开信息，但本公司不保证该等信息的准确性或完整性。本报告所载的信息、资料、分析工具、意见及推测只提供给客户作参考之用，并非作为或被视为出告或购买证券或其他投资标的的投资建议或要约邀请。本报告所指的证券或投资标的的价格、价值及投资收入可能会波动。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告。本公司建议客户应考虑本报告的任何意见或建议是否符合其特定状况，以及(若有必要)咨询独立投资顾问。在法律许可的情况下，本公司及其所属关联机构可能会持有本报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些公司提供或争取投资银行业务服务或其他服务。免责条款本报告是为特定客户和其他专业人士提供的参考资料。文中所有内容均代表个人观点。本公司力求报告内容的准确可靠，但并不对报告内容及所引用资料的准确性和完整性作出任何承诺和保证。本公司不会承担因使用木报告而产生的法律责任。本报告版权归国元证券所有，未经授权不得复印、转发或向特定读者群以外的人士传阅，如需引用或转载本报告，务必与本公司研宄中心联系。网址:www.gyzq.com.cn","data":[{"id":"1","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"8月血制品总计实现批签发756.53万瓶","content_offset":["303","323"],"indicators":[{"indicator_name":"批签发量","indicator_value":["756.53万瓶","315","323"],"indicator_element":{"时间":["8月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比下降6.59%","content_offset":["324","333"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降6.59%","326","333"],"indicator_element":{"时间":["8月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"环比增长12.79%","content_offset":["334","344"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["增长12.79%","336","344"],"indicator_element":{"时间":["8月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"2020年1-8月累计批签发6437万瓶","content_offset":["345","365"],"indicators":[{"indicator_name":"批签发量","indicator_value":["6437万瓶","359","365"],"indicator_element":{"时间":["2020年1-8月","345","354"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比增长27.77%","content_offset":["366","376"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长27.77%","368","376"],"indicator_element":{"时间":["2020年1-8月","345","354"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"白蛋白本月累计批签发481.27万瓶","content_offset":["394","412"],"indicators":[{"indicator_name":"批签发量","indicator_value":["481.27万瓶","404","412"],"indicator_element":{"时间":["本月","397","399"],"产品":["白蛋白","394","397"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比增长12.04%","content_offset":["413","423"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长12.04%","415","423"],"indicator_element":{"时间":["本月","397","399"],"产品":["白蛋白","394","397"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"其中进口占52.59%","content_offset":["424","435"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["52.59%","429","435"],"indicator_element":{"时间":["本月","397","399"],"产品":["白蛋白","394","397"],"渠道":["进口","426","428"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"本月国产白蛋白批签量创今年来新高(达228.16万瓶)","content_offset":["463","490"],"indicators":[{"indicator_name":"批签发量","indicator_value":["228.16万瓶","481","489"],"indicator_element":{"时间":["本月","463","465"],"产品":["白蛋白","467","470"],"渠道":["国产","465","467"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"静丙本月批签发98.32万瓶","content_offset":["515","529"],"indicators":[{"indicator_name":"批签发量","indicator_value":["98.32万瓶","522","529"],"indicator_element":{"时间":["本月","517","519"],"产品":["静丙","515","517"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比下降18.52%","content_offset":["530","540"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降18.52%","532","540"],"indicator_element":{"时间":["本月","444","446"],"产品":["静丙","515","517"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"白蛋白批签发481.27万瓶","content_offset":["1162","1176"],"indicators":[{"indicator_name":"批签发量","indicator_value":["481.27万瓶","1168","1176"],"indicator_element":{"时间":["8月","1109","1111"],"产品":["白蛋白","1162","1165"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比增长12.04%","content_offset":["413","423"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长12.04%","415","423"],"indicator_element":{"时间":["8月","352","354"],"产品":["白蛋白","394","397"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"其中进口白蛋白批签发253.11万","content_offset":["1188","1205"],"indicators":[{"indicator_name":"批签发量","indicator_value":["253.11万","1198","1205"],"indicator_element":{"时间":["8月","1109","1111"],"产品":["白蛋白","1192","1195"],"渠道":["进口","1190","1192"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"占52.59%","content_offset":["428","435"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["52.59%","429","435"],"indicator_element":{"时间":["8月","352","354"],"产品":["白蛋白","394","397"],"渠道":["进口","426","428"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"国产白蛋白批签发228.16万","content_offset":["1229","1244"],"indicators":[{"indicator_name":"批签发量","indicator_value":["228.16万瓶","-1","-1"],"indicator_element":{"时间":["8月","2947","2949"],"产品":["白蛋白","1231","1234"],"渠道":["国产","1229","1231"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"本月狂免批签发92.66万、破免31.70万、乙免5.03万、肌丙12.39万、纤原5.94万、八因子21.75万、PCC7.46万","content_offset":["1352","1418"],"indicators":[{"indicator_name":"批签发量","indicator_value":["92.66万","1359","1365"],"indicator_element":{"产品":["狂免","1354","1356"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["31.70万","1368","1374"],"indicator_element":{"产品":["破免","1366","1368"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["5.03万","1377","1382"],"indicator_element":{"产品":["乙免","1375","1377"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["12.39万","1385","1391"],"indicator_element":{"产品":["肌丙","1383","1385"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["5.94万","1394","1399"],"indicator_element":{"产品":["纤原","1392","1394"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["21.75万","1403","1409"],"indicator_element":{"产品":["八因子","1400","1403"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["7.46万","1413","1418"],"indicator_element":{"产品":["PCC","1410","1413"],"时间":["本月","1352","1354"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"本月纤原批签发5.94万瓶","content_offset":["2662","2675"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5.94万瓶","2669","2675"],"indicator_element":{"时间":["本月","2662","2664"],"产品":["纤原","2664","2666"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比下降9.22%","content_offset":["2676","2685"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降9.22%","2678","2685"],"indicator_element":{"时间":["本月","2662","2664"],"产品":["纤原","2664","2666"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"本月八因子批签发21.75万瓶","content_offset":["2703","2718"],"indicators":[{"indicator_name":"批签发量","indicator_value":["21.75万瓶","2711","2718"],"indicator_element":{"时间":["本月","2703","2705"],"产品":["八因子","2705","2708"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年08月血制品行业批签发跟踪.pdf","content":"同比增长15.96%","content_offset":["2719","2729"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长15.96%","2721","2729"],"indicator_element":{"时间":["本月","2662","2664"],"产品":["八因子","2705","2708"]},"indicator_supplement":{"属性":""}}]}]}